Skip to content

A new method to treat mild cognitive impairment, meditation and its neuroregulatory mechanism

Meditation for the treatment of mild cognitive impairment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061075
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

impairment cognitive disorder

Interventions

group 1:control the risk factors of mild cognitive impairment
group 2:meditation and control the risk factors of mild cognitive impairment

Sponsors

Kangci Hospital of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of mild cognitive impairment; 2. Aged >= 50 years, no sex limitation; 3. MMSE score > 19 in patients with primary school education, or >24 in patients with middle school education or higher levels; CDR score <= 0.5; and ADL score < 16, MoCA score ranging from 23 to 26; 4. HAMD-17 score <= 7, HAMA <= 7, and BPRS score < 35; 5. Each patient should be willing to participate in this study, he/she and his/her guardian must sign the informed consent form after understanding the nature of this study.

Exclusion criteria

Exclusion criteria: 1. Dementia or mental retardation; 2. Anxiety, depression, or other psychotic symptoms; 3. Severe physical diseases which affect cognitive function; 4. Substance addiction or behavioral disorders which affect cognitive function; 5. Illiterate subjects.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment;

Secondary

MeasureTime frame
Trail-making Test A;Trail-making Test B;Boston naming test;Hopkins Verbal Learning Test;clock drawing test;fNIRS;heart rate variability;function of HPA axis;serum level of NE;serum level of 5-TH;serum level of Ach;serum level of BDNF;serum level of IL-1ß;serum level of IL-6;serum level of TNF-a;

Countries

China

Contacts

Public ContactPu Zhengping
440391221@qq.com+86 13806717447

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026